Emily Wang is the Director of USMA Strategic Execution at Gilead Sciences, specializing in medical affairs strategy and operations. Her career includes key roles at Merck and ZS. Emily holds a Masters degree from Rutgers University and a Bachelors degree from Princeton University, underpinning her expertise in the pharmaceutical sector.
She transitioned from a foundational role in healthcare consulting at ZS to senior strategic positions at major pharmaceutical companies.
Emily Wang
Director, USMA Strategic Execution at Gilead Sciences
New York City Metropolitan Area, United States
Overview
Topics They Care About
Medical Affairs
Her career is centered on Medical Affairs, with leadership roles focusing on strategy and strategic execution at both Gilead Sciences and Merck.
Strategic Execution
Her current director-level role at Gilead Sciences explicitly focuses on the strategic execution and implementation of medical affairs initiatives in the US.
Pharmaceutical Operations
She has a background in managing strategy and operations from her time at Blink Health and as a consultant at ZS Associates.
Media Appearances
Emily has no verified media appearances
Work History
1-2026
Director, USMA Strategic Execution at Gilead Sciences
1-2024 - 1-2026
Associate Director, Medical Affairs at Merck
12-2021 - 1-2024
Scientific Leadership and Research Manager at Merck
6-2021 - 11-2021
Client Strategy and Operations Manager at Blink Health
12-2020 - 6-2021
Associate Consultant at ZS
7-2018 - 12-2020
Decision Analytics Associate at ZS
6-2017 - 8-2017
MMD IT and Analytics Intern at Merck
Education
2016 - 2018
Master’s Degree from Rutgers University
2012 - 2016
Bachelor’s Degree from Princeton University
More Information
Social Presence :
Prographics :
Exp : 7
Location : New York City Metropolitan Area, United States
Job Level : Mid-senior
Designation : Director, USMA Strategic Execution at Gilead Sciences
